Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.52 |
| ▸ | CYP46A1 | Q9Y6A2 | 6/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941766 | 1.00 | AR (0.52) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL524307 | 0.86 | AR (0.50) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL14525275 | 0.86 | AR (0.56) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL30436667 | 0.86 | AR (0.50) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL524308 | 0.86 | AR (0.50) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL14034147 | 0.83 | AR (0.47) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL17046817 | 0.81 | AR (0.46) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL17046816 | 0.81 | AR (0.46) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL18548775 | 0.81 | AR (0.46) | ARCYP46A1NR3C1NR1I2PGR | |
| SCHEMBL13685998 | 0.79 | AR (0.47) | ARCYP46A1MAPTPDK1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | claimed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | claimed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676735-B2 | Process for the preparation of efavirenz and devices suitable therefore | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-03-02 | — | — | US | disclosed |
| WO-2012097511-A1 | DMP-266 BY CYCLISATION | LONZA LTD (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097510-A1 | PROCESS FOR PREPARATION OF EFAVIRENZ BY CYCLISATION | LONZA LTD (CH) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012079235-A1 | PROCESS FOR PREPARING EFAVIRENZ | LONZA LTD (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057937-A1 | Process for the preparation of Efavirenz and devices suitable therefore | CYP3A4, CYP2C19, CYP3A43 | AR 3329/4885CYP46A1 120/4885NR3C1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.